Parkinson's disease: Cell death mechanisms;Maladie de Parkinson: Mécanismes de la mort cellulaire

Revue Neurologique

Volumn 158, Issue SUPPL. 1, 2002, Pages

  Michel, P P ^a   Hirsch, E C ^a   Agid, Y ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; PARKIN; PROTEIN; REACTIVE OXYGEN METABOLITE; UCHL 1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTE; CELL DEATH; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; GENE MUTATION; GLIA CELL; HUMAN; MICROGLIA; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NEUROTOXICITY; PARKINSON DISEASE; PROTEIN DEGRADATION;

EID: 0036907497     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Abbas N, Lücking CB, Ricard S, et al. (1999). A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum Mol Genet, 8: 567-574.
2. Agid Y. (1991). Parkinson's disease: Pathophysiology. Lancet, 337: 1321-1324.
3. Anglade P, Vyas S, Javoy-Agid F, et al. (1997). Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol and Histopathol, 12: 25-31.
4. Arock M, Le Goff L, Becherel PA, et al. (1994). Involvement of Fc(epsillon)RII/CD23 and L-arginine dependant pathway in IgE-mediated activation of human eosinophils. Biochem Biophys Res Commun, 203: 265-271.
5. Betarbet R, Sherer T.B., Mckenzie G, et al. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci, 3: 1301-1306.
6. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. (1994). Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett, 172: 151-154.
7. Chung KK, Zhang Y, Lim KL, et al. (2001). Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: Implications for Lewy-body formation in Parkinson disease. Nat Med, 7:1144-1150.
8. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F. (1993). Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience, 52: 1-6.
9. Damier P, Hirsch EC, Agid Y, Graybiel AM. (1999). The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain, 122: 1437-1448.
10. Darios F, Corti O, Lücking C, Gu WJ, Brice A, Ruberg M. (2002). Protective effect of Parkin against ceramide-mediated cell death. FENS Abstr., 1: 153.
11. Delespesse G, Sutter U, Mossalayi MD, et al. (1991). Expression, structure, and function of the CD23 antigen. Adv Immunol, 49: 149-191.
12. Dugas B, Mossalayi MD, Damais C, Kolb JP. (1995). Nitric oxide production by human monocytes: Evidence for a role of CD23. Immunol Today, 16: 574-580.
13. Farrer M, Chan P, Chen R, et al. (2001). Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol, 50: 293-300.
14. Faucheux BA, Bonnet AM, Agid Y, Hirsch EC. (1999). Blood vessels change in the mesencephalic of patients with Parkinson's disease. Lancet, 353: 981-982.
15. Giasson BI, Lee VM. (2001). Parkin and the molecular pathways of Parkinson's disease. Neuron, 31: 885-8.
16. Gu WJ, Abbas N, Lagunes MZ, Parent A, Pradier L, Bohme GA, Agid Y, Hirsch EC, Raisman-Vozari R, Brice A. (2000). Cloning of rat parkin cDNA and distribution of parkin in rat brain. J Neurochem, 74: 1773-1776.
17. Good PF, Hsu A, Werner P, Perl DP, Olanow CW. (1998). Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol, 57: 338-342.
18. Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Matthews RT, Beal MF. (1996). Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med, 2: 1017-1021.
19. Hartmann A, Hunot S, Michel PP, et al. (2000). Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA, 97: 2875-2880.
20. Hartmann A, Troadec J-D, Hunot S, et al. (2001). Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci, 21: 2247-2255.
21. Hirsch EC, Hunot S, Hartmann A. (2000). Mechanism of cell death in experimental models of Parkinson's disease. Functional Neurology, 15: 229-237.
22. Hirsch EC, Faucheux B, Damier P, Mouatt-Prigent A, Agid Y. (1997). Neuronal vulnerability in Parkinson's disease. J Neural Transm, Suppl 50: 79-88.
23. Hunot S, Boissiècre F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC. (1996). Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience, 72: 355-363.
24. Hunot S, Dugas N, Faucheux B, et al. (1999). Fc(epsilon)RII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and Tumor Necrosis Factor-alpha in glial cells. J Neurosci, 19: 3440-3447.
25. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM. (1991). BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature, 350: 230-232.
26. Imai Y, Soda M, Takahashi R. (2000). Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem, 275: 35661-35664.
27. Joazeiro CA, Weissman AM. (2000). RING finger proteins: Mediators of ubiquitin ligase activity. Cell, 102: 549-552.
28. Kahns S, Lykkebo S, Jakobsen LD, Nielsen MS, Jensen PH. (2002). Caspase-mediated parkin cleavage in apoptotic cell death. J Biol Chem, 277:15303-15308.
29. Kitada T, Asakawa S, Hattori N, et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392: 605-608.
30. Kubis N, Faucheux BA, Ransmayr G, et al. (2000). Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain, 123: 366-373.
31. Liberatore GT, Jacksonlewis V, Vukosavic S, et al. (1999). Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nature Med, 5: 1403-1409.
32. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. (1993). GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science, 260: 1130-1132.
33. Lücking CB, Dürr A, Bonifati V, et al. and For the European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group. (2000). Early onset parkinsonism and parkin gene mutations. New Engl J Med, 342: 1560-1567.
34. Masliah E, Rockenstein E, Veinbergs I, et al. (2000). Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science, 287: 1265-1269.
35. Matthews RT, Beal MF, Fallon J, Fedorchak K, Huang PL, Fishman MC, Hyman BT. (1997). MPP+ induced substantia nigra degeneration is attenuated in nNOS knockout mice. Neurobiol Dis, 4: 114-121.
36. Mcnaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. (2001). Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci, 2: 589-594,
37. Mogi M, Harada M, Kondo J, Riederer P, Inagaki H, Minami M, Nagatsu T. (1994). Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett, 180: 147-150.
38. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. (1994). Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett, 165: 208-210.
39. Mogi M, Togari A, Tanaka K, Ogawa N, Ichinose H, Nagatsu T. (1999). Increase in level of Tumor Necrosis Factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction. Neurosci Lett, 268: 101-104.
40. Mossalayi MD, Paul-Eugène N, Ouaaz F, et al. (1994). Involvement of Fc(epsilon) RII/CD23 and L-arginine-dependant pathway in IgE-mediated stimulation of human monocyte functions. Int Immunol, 6: 931-934,
41. Mouradian MM. (2002). Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology, 58: 179-85.
42. Polymeropoulos MH, Lavedan C, Leroy E, et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276: 2045-2047.
43. Przedborski S, Jackson-Lewis V, Yokoyama R, Dawson VL, Dawson TM. (1996). Role of neuronal nitric oxide in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA, 93: 4565-4571.
44. Qureshi GA, Baig S, Bednar I, Sodersten P, Forsberg G, Siden A. (1995). Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. NeuroReport, 6: 1642-1644.
45. Saigoh K, Wang YL, Suh JG, et al. (1999). Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet, 23: 47-51.
46. Stichel CC, Augustin M, Kuhn K, Zhu XR, Engels P, Ullmer C, Lubbert H. (2000). Parkin expression in the adult mouse brain. Eur J Neurosci, 12: 4181-4194.
47. Tanaka Y, Engelender S, Igarashi S, et al. (2001). Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet, 10: 919-926
48. Wintermeyer P, Kruger R, Kuhn W, et al. (2000). Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport, 11: 2079-2082.
49. Yeh WC, Hakem R, Woo M, Mak TW. (1999). Gene targeting in the analysis of mammalian apoptosis and TNF receptor superfamily signaling. Immunol Rev, 169: 283-302.